JCOG0605_2B: JCOG0605, figure 2B

JCOG0605_2BR Documentation

JCOG0605, figure 2B

Description

Kaplan-Meier digitized data from JCOG0605, figure 2B (PMID 27312053). A reported sample size of 180 for a primary endpoint of OS in lung cancer.

Usage

JCOG0605_2B

Format

A data frame of 180 observations and 3 variables:

time event time (in months)
event PFS event indicator (0: no event, 1: event)
arm treatment arms (combination_chemotherapy, topotecan)

Source

Goto K, Ohe Y, Shibata T, et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2016; 17: 1147–57.

Examples

summary(JCOG0605_2B)

kmplot(JCOG0605_2B)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.